catheter securement

Join Us at Medica 2015 in Dusseldorf!

Matt Geary Blogs, Company News Comments Off on Join Us at Medica 2015 in Dusseldorf! , , , ,


MedicaKicking off on November 16th – the Medica tradeshow is the world largest event for the medical sector. BioDerm is attending for the second straight year! Featuring over 4800 companies and 130,000 attendees, Medica is a once a year opportunity to promote our products to a growing international audience.

If you or someone you know if going to be in Dusseldorf – please come and visit! We will be located in the Florida Pavilion – Halle 16, Stand D04. We will have both our National Sales Manager, Jim Terpstra, and our Clinical Marketing Specialist, Sarah Woodward in attendance to answer all your questions.

BioDerm is currently seeking new distribution relationships in Europe, Asia and South America. We currently export to Canada, Peru, the Netherlands and the United Kingdom. BioDerm is a manufacturer of hydrocolloid urological and catheter securement products. We provide high quality, innovative product solutions that reduce healthcare costs by preventing avoidable complications in the acute care and consumer marketplace.

For more information on our products please download our Corporate Profile!

Medical Device Related Pressure Ulcers: White Paper Published!

Matt Geary Catheter Securement, Company News Comments Off on Medical Device Related Pressure Ulcers: White Paper Published! , , , , ,

Best Practices to Prevent Medical Device Related Pressure Ulcers!


Pressure ulcers cost the US healthcare system more than $11 billion dollars annually. With over 1/3 of those costs associated with medical device usage, clinicians, manufacturers and purchasing have a unique opportunity to implement a coordinated strategy to reduce or eliminate these ulcerations.

Portrait of an African patient lying in his bed with his nurse by his side

Portrait of an African patient lying in his bed with his nurse by his side

Medical device related pressure ulcers (MDR-PU) are unique due to their development away from the traditional bony prominences seen with other pressure ulcers. In addition, they are much more likely to be identified at a later stage of development (74%)2, increasing treatment costs (Avg: $10,700)11 and length of stay (adding 4-10 days excess LOS)5.

In order to assist acute care facilities in reducing the clinical and financial burden of these events, we have identified the key components of a risk mitigation protocol. This includes interventions from clinicians, modifications of purchasing processes and partnerships with medical device manufacturers to build in risk mitigation from the outset. Implementation of these protocols may help reduce the cost and incidence of medical device related ulcers.